Brieflands
Journal finderSearch
·
Sign in

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

e-ISSN 1735-3408
p-ISSN 1735-143X
Home
Articles
    Current IssueAccepted ManuscriptsAll IssuesIn Press ArticlesSearch
Instructions
About Journal
    Journal InformationBoards and committeesIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit manuscript
  1. Brieflands
  2. /
  3. journals
  4. /
  5. Hepatitis Monthly
  6. /
  7. Articles
  8. /
  9. Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience
  10. /
  11. Scopus by Title (Ref)
Citation data

Scopus by Title (Ref)

Articles that cite the referenced work, matched by title from the Scopus database.

4 results·Updated October 22, 2026
← Back to article
1

Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients

Medicine United States

14 July 2023

Mohamed Abdelnajid D.

Open Access

2

Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)

Journal of Medical Virology

1 December 2020

Wahid B.

3

Sofosbuvir and ribavirin combination therapy response in various hepatitis C virus genotypes in Peshawar, Khyber Pakhtunkhwa

Jundishapur Journal of Microbiology

2020

Haider S.A.

Open Access

4

Efficacy of Sofosbuvir and Ribavirin therapy in hepatitis C virus infection among treatment Naïve cases of south Punjab

Medical Forum Monthly

September 2017

Malghani W.S.

Need help?

Editorial, submission and technical questions all go to the same desk.

Submit a ticket
Brieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.